FDA Brief

Warning letters Drugs

FDA warning letter to

Larkin Community Hospital Institutional Review Board

MediumIssued Jan 11, 2023Posted Jan 24, 2023Center for Drug Evaluation and Research | CDER

Larkin Community Hospital IRB cited for approving trials without required nonscientist member and incomplete records.

What happened

FDA inspected the Larkin Community Hospital Institutional Review Board from November 12 to November 19, 2021, and reviewed records and the IRB's later written response. FDA found that the IRB approved FDA-regulated research at five convened meetings without a majority that included at least one nonscientific member. FDA also found an inadequate IRB membership list and missing required ClinicalTrials.gov statements in consent documents for two COVID-19 clinical trials.

What FDA found

  1. The IRB reviewed and approved FDA-regulated research at meetings that did not have a majority of members present, including at least one nonscientific member.

    21 CFR 56.108(c)
  2. The IRB did not prepare and maintain a complete list of IRB members from July 2019 to March 2021, including required details such as representative capacity and relationships with the institution.

    21 CFR 56.115(a)(5)
  3. The IRB did not ensure that informed consent documents for two applicable drug clinical trials included the required statement about ClinicalTrials.gov.

    21 CFR 56.109(b); 21 CFR 50.25(c)

What FDA wants

FDA asks the IRB to notify it in writing within 15 business days of actions planned or taken, provide a corrective action plan to prevent repeat violations, and submit a current membership list that meets 21 CFR 56.115(a)(5).

Who should pay attention

  • clinical trial sponsors relying on this IRB
  • investigators and research sites using its approvals
  • other IRBs and human-subject protection offices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk